Search

Acute myocardial infarction (AMI) is a serious and fatal heart disease with one of the highest mortality rates in the world. In some countries, percutaneous coronary intervention (PCI) is the preferred reperfusion strategy after AMI, but it cannot achieve safe and effective treatment of AMI after PCI remains a challenging clinical problem. The potential of oral Chinese patent medicines to treat AMI after PCI has been demonstrated, but which type of oral Chinese patent medicines may be preferred remains controversial. The aim of this network meta-analysis was to investigate the efficacy and safety of multiple oral Chinese patent medicines in the treatment of AMI after PCI.We will conduct a literature search from China National Knowledge Infrastructure, formerly Chinese Biomedical Database (SinoMed), Wanfang Data, Chongqing VIP, PubMed, Embase, Web of Science and Cochrane Library (The Cochrane Database of Systematic Reviews) from their inception until to November 1, 2022, with language restricted to Chinese and English. Then, the study selection process will follow the Preferred Reporting Items for Meta-Analyses guideline, and the quality assessment will be conducted with Cochrane Collaboration's tool. Pairwise and network meta-analysis will be conducted using the WinBUGS V.1.4.3.37 and STATA V.13. Additionally, sensitivity analysis, subgroup analysis, quality assessment, Small-study effects and publication bias will be performed.This work is based on published research and therefore does not require ethical approval. This review will be published in peer-reviewed journals.CRD42020188065.

Objective: To evaluate the effect of existing acupuncture-related therapies on the longterm effects of post-stroke depression (PSD) by using a network meta-analysis with SSRIs as a common reference. Methods: The published randomized controlled clinical trials of acupuncture-related therapies and SSRIs for PSD in PubMed, The Cochrane Library, EMbase, CNKI, CBM, VIP and wan-fang databases were comprehensively searched. The literature retrieval period was from The database establishment to July 31, 2020. Cochrane Handbook 5.1.0 was used to assess the risk of bias in included studies. Data analysis is conducted through ADDIS, Review Manager 5.3, and STATA 13.1 software. Results: A total of 3115 patients with PSD were included in 30 RCTs, involving 10 therapeutic methods. Results of network meta-analysis showed that: in terms of total effective rate, body acupuncture +SSRIs was superior to body acupuncture [OR=2.85, 95%CI (1.51, 5.90)] and SSRIs[OR=5.37, 95%CI (3.03, 10.33)]. In terms of HAMD score, body acupuncture +SSRIs was superior to body acupuncture [MD=1.69, 95%CI(0.33, 3.06)] and SSRIs[MD=3.87, 95% CI(2.68, 5.08)]. The above ranking predicted that moxibustion +SSRIs was the best. In terms of NIHSS score, body acupuncture [MD=2.15, 95% CI(1.10, 3.26)] and body acupuncture +SSRIs[MD=1.77, 95%CI(0.19, 3.37)] were better than SSRIs. Conclusion: Moxibustion combined with SSRIs is the best for the long-term efficacy of acupuncture and moxibustion on PSD. Body acupuncture combined with SSRIs is better than SSRIs alone. The other therapies have their own advantages and disadvantages. Based on the defects of existing studies, this conclusion still needs to be verified by more high-quality RCTs.

IntroductionTotal knee arthroplasty (TKA) is currently regarded as an effective treatment for knee osteoarthritis, relieving patients’ pain and significantly enhancing their quality of life and activity levels, allowing them to return to work and daily life after surgery. However, some TKA patients suffer from varying degrees of postoperative residual pain and opioid abuse, which negatively impacts their recovery and quality of life. It has been reported that preoperative treatment with multimodal analgesics improves postoperative pain and reduces opioid consumption. However, there is no conclusive evidence that pre-emptive analgesia provides the same benefits in TKA. In order to inform future research, this protocol focuses on the efficacy and safety of oral analgesics used in TKA pre-emptive analgesia.Methods and analysisWe will search the literature on the involvement of pre-emptive analgesia in the management of pain in TKA from the PubMed, EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews, from their inception to 1 February 2023. Additionally, clinical registry platforms will be investigated to collect data for ongoing studies. Using the Cochrane Risk of Bias Tool, the quality assessment will be conducted. RevMan V.5.4 will be used for the meta-analysis. The statisticI2will be used to measure the percentage of total variability due to heterogeneity between studies. Where appropriate, subgroup and sensitivity analyses, assessment of evidence quality and publication bias will be conducted.Ethics and disseminationNo ethical approval and consent is required for this systematic review. Moreover, the results of this systematic review will be disseminated through peer-reviewed publications and conference presentations.PROSPERO registration numberCRD42022380782.